Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggest aspirin did not improve outcomes in older adults with chronic kidney disease.

The role of aspirin for primary prevention in older adults with chronic kidney disease (CKD) is unclear. Therefore, post hoc analysis of the randomized controlled trial ASPirin in Reducing Events in the Elderly (ASPREE) was undertaken comparing 100 mg of enteric-coated aspirin daily against matching placebo. Participants were community dwelling adults aged 70 years and older in Australia, 65 years and older in the United States, all free of a history of dementia or cardiovascular disease and of any disease expected to lead to death within five years.

Source: Kidney International - September 9, 2020 Category: Urology & Nephrology Authors: Rory Wolfe, James B. Wetmore, Robyn L. Woods, John J. McNeil, Hugh Gallagher, Paul Roderick, Rowan Walker, Mark R. Nelson, Christopher M. Reid, Raj C. Shah, Michael E. Ernst, Jessica E. Lockery, Andrew M. Tonkin, Walter P. Abhayaratna, Peter Gibbs, Erica Tags: clinical trial Source Type: research